Novo Nordisk or Eli Lilly? The Billion-Dollar GLP-1 Battle Is Heating Up
The global pharmaceutical industry is witnessing one of the biggest healthcare competitions in history. Two industry giants—Novo Nordisk and Eli Lilly—are …
Healthcare Innovation
Digital Therapeutics (DTx) in 2026: How Software Is Becoming the Next Prescription Medicine
Healthcare is entering a new digital era where software is becoming an important part of patient care. While medicines, medical devices, …
FDA Approves Historic Gene Therapy for Children—A New Milestone in Modern Medicine
The U.S. Food and Drug Administration (FDA) has approved the first gene therapy for young children with sickle cell disease, marking …
Eli Lilly Expands U.S. Manufacturing in 2026: What It Means for GLP-1 Drugs, Pharma Jobs, and Healthcare Innovation
The demand for GLP-1 medicines used in diabetes care and, where approved, chronic weight management has grown rapidly in recent years. …
$10 Billion Pharma Deal Could Transform Rare Disease Treatments
The pharmaceutical industry has witnessed another major acquisition as Vertex Pharmaceuticals announced an agreement to acquire Crinetics Pharmaceuticals in a transaction …
Generic GLP-1 Drugs Could Change the Weight-Loss Market—FDA Begins Review
The U.S. market for GLP-1 medicines continues to expand rapidly as demand for obesity and diabetes treatments grows. In another important …
FDA Approves Sanofi’s Wearable Cancer Drug Device—A Big Step for Cancer Care
The U.S. Food and Drug Administration (FDA) has approved a wearable injector version of Sanofi’s blood cancer medicine Sarclisa for eligible …
Top 15 AI Companies Transforming Drug Discovery in 2026: The Future of Pharmaceutical Innovation
Artificial intelligence is rapidly becoming one of the most influential technologies in pharmaceutical research. What once required years of laboratory screening …